Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is one of the best cheap biotech stocks to buy now. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) reported financial results for the three and twelve months ended December 31, 2025, on February 26, 2026. It reported that total revenue for the three and twelve months was $77.1 million and $283.1 million, up 29% and 20%, respectively, compared to $59.9 million and $235.1 million in the prior year periods, respectively.
Net product sales of LUPKYNIS, which is the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $74.2 million and $271.3 million for the three and twelve months, up 29% and 25%, respectively, compared to $57.6 million and $216.2 million for the same periods of 2024, respectively.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) further reported that it has cash, cash equivalents, restricted cash, and investments of $398.0 million as of December 31, 2025, compared to $358.5 million in the prior year period. It also repurchased 12.2 million of its common shares for $98.2 million in the year 2025. For 2026, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) expects total revenue of $315 million to $325 million, up 11% to 15% compared to 2025, and net product sales of $305 million to $315 million, up 12% to 16% compared to 2025.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a clinical-stage bio-pharmaceutical company involved in the research, development, and commercialization of therapeutic drugs.
While we acknowledge the potential of AUPH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.